As HER3 has shown expression across solid tumors, the introduction of emerging HER3-directed antibody-drug conjugates (ADCs) as a potential treatment for breast and non-small-cell lung cancers (NSCLCs) has been a welcome development. Learn more about these exciting novel agents as the faculty provides in-depth answers to common questions from oncology clinicians during this engaging Ask the Experts discussion.
- Provider:Paradigm Medical Communications, LLC
- Activity Link: https://ce.paradigmmc.com/a/ZONTRG
- Start Date: 2024-07-31 05:00:00
- End Date: 2024-07-31 05:00:00
- Credit Details: AMA PRA Category 1 Credit™️: 0.25 hours
- Commercial Support: Source: Daiichi Sankyo, Inc. - Amount: 95425.0 - Is Kind Support: False
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: No, it's free
- Measured Outcome: Learner Competence, Learner Knowledge
- Provider Ship: Directly Provided
- Registration: Open to all
Subscribe
Login
0 Comments
Oldest